Literature DB >> 28495977

Modelling the implications of reducing smoking prevalence: the public health and economic benefits of achieving a 'tobacco-free' UK.

Daniel Hunt1, André Knuchel-Takano2, Abbygail Jaccard2, Arti Bhimjiyani3, Lise Retat2, Chit Selvarajah1, Katrina Brown4, Laura L Webber2, Martin Brown2.   

Abstract

INTRODUCTION: Smoking is still the most preventable cause of cancer, and a leading cause of premature mortality and health inequalities in the UK. This study modelled the health and economic impacts of achieving a 'tobacco-free' ambition (TFA) where, by 2035, less than 5% of the population smoke tobacco across all socioeconomic groups.
METHODS: A non-linear multivariate regression model was fitted to cross-sectional smoking data to create projections to 2035. These projections were used to predict the future incidence and costs of 17 smoking-related diseases using a microsimulation approach. The health and economic impacts of achieving a TFA were evaluated against a predicted baseline scenario, where current smoking trends continue.
RESULTS: If trends continue, the prevalence of smoking in the UK was projected to be 10% by 2035-well above a TFA. If this ambition were achieved by 2035, it could mean 97 300 +/- 5 300 new cases of smoking-related diseases are avoided by 2035 (tobacco-related cancers: 35 900+/- 4 100; chronic obstructive pulmonary disease: 29 000 +/- 2 700; stroke: 24 900 +/- 2 700; coronary heart disease: 7600 +/- 2 700), including around 12 350 diseases avoided in 2035 alone. The consequence of this health improvement is predicted to avoid £67 +/- 8 million in direct National Health Service and social care costs, and £548 million in non-health costs, in 2035 alone.
CONCLUSION: These findings strengthen the case to set bold targets on long-term declines in smoking prevalence to achieve a tobacco 'endgame'. Results demonstrate the health and economic benefits that meeting a TFA can achieve over just 20 years. Effective ambitions and policy interventions are needed to reduce the disease and economic burden of smoking. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  End game; disease burden; economic burden; tobacco microsimulation; tobacco-free

Mesh:

Year:  2017        PMID: 28495977     DOI: 10.1136/tobaccocontrol-2016-053507

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  6 in total

1.  Socioeconomic inequalities in children's exposure to tobacco retailing based on individual-level GPS data in Scotland.

Authors:  Fiona Caryl; Niamh K Shortt; Jamie Pearce; Garth Reid; Richard Mitchell
Journal:  Tob Control       Date:  2019-07-05       Impact factor: 7.552

2.  Impact of tobacco control policies implementation on future lung cancer incidence in Europe: An international, population-based modeling study.

Authors:  Thomas Gredner; Ute Mons; Tobias Niedermaier; Hermann Brenner; Isabelle Soerjomataram
Journal:  Lancet Reg Health Eur       Date:  2021-05

3.  Future smoking prevalence by socioeconomic status in England: a computational modelling study.

Authors:  Fujian Song; Tim Elwell-Sutton; Felix Naughton; Sarah Gentry
Journal:  Tob Control       Date:  2020-05-23       Impact factor: 7.552

4.  [Smoke-free Germany 2040: a discussion paper].

Authors:  Reiner Hanewinkel; Matthis Morgenstern; Barbara Isensee; Friedrich J Wiebel
Journal:  Dtsch Med Wochenschr       Date:  2020-06-22       Impact factor: 0.628

5.  Impact of the NHS Stop Smoking Services on smoking prevalence in England: a simulation modelling evaluation.

Authors:  Fujian Song; Tim Elwell-Sutton; Felix Naughton
Journal:  Tob Control       Date:  2019-04-05       Impact factor: 7.552

6.  Mining Electronic Health Records to Promote the Reach of Digital Interventions for Cancer Prevention Through Proactive Electronic Outreach: Protocol for the Mixed Methods OptiMine Study.

Authors:  Michael S Amato; Sherine El-Toukhy; Lorien C Abroms; Henry Goodfellow; Alex T Ramsey; Tracey Brown; Helena Jopling; Zarnie Khadjesari
Journal:  JMIR Res Protoc       Date:  2020-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.